Table 2.
Parameters | No. of patients | ||||
---|---|---|---|---|---|
New diagnosed patients n = 76 | Healthy volunteers n = 40 | Patients after an induction treatment | |||
After the treatment n = 71 | With CR n = 44 | With NR n = 27 | |||
TRAIL [pg/ml] | 68.54 (19.1–104.8) | 79.9* (55.4–108.2) | 56.52 (19.3–158.8) | 74.2 (35.22–158.8) | 50.56*** (19.3–88.28) |
BAFF [pg/ml] | 3615.1 (983.9–9151.4) | 651.4* (362.9–1122.3) | 3058.1** (972.3–8923.4) | 1885.1 (972.3–7645.4) | 5036.4*** (1538.2–8923.4) |
APRIL [ng/ml] | 5.96 (1.65–43.4) | 1.68* (1.0–7.56) | 5.56 (1.4–69.9) | 3.42 (1.4–19.2) | 8.89*** (2.1–69.9) |
TNF [pg/ml] | 9.06 (3.92–83.4) | 5.35 * (3.12–7.4) | 8.62** (3.8–69.1) | 8.51 (3.8–43.1) | 9.13 (3.9–69.1) |
IL-6 [pg/ml] | 12.12 (1.96–43.4) | 1.92* (0.87–2.43)* | 8.64** (0.57–155.4) | 5.42 (0.57–20.1) | 19.4*** (4.57–155.4) |
The values are presented as median (range)
AML acute myeloid leukaemia, BAFF B cell-activating factor, APRIL a proliferation-inducing ligand, TRAIL TNF-related apoptosis-inducing ligand, TNF tumour necrosis factor, IL-6 interleukin 6, CR complete remission, NR non-responders
*p < 0.05 between AML patients and healthy volunteers
**p < 0.05 between before and after treatment AML patients
***p < 0.05 between patients with CR and NR